As the last resort and one of the most crucial antibiotics for multidrug-resistant bacteria, carbapenem is considered the best hope for treating bacterial infections. However, the prompt emergence of carbapenemase-producing bacteria (CPB) poses a striking global health threat. Thus, accurate and rapid methods for the detection of carbapenemase are being requested to guide precise diagnosis, appropriate treatment strategies, and antibiotic stewardship. Although genotypic, phenotypic, and biochemical methods are currently used in clinical practice for CPB detection, they each have their problems that cannot commendably meet the need. In recent years, small-molecule probes have made significant progress and breakthroughs in the rapid detection and subtyping of CPB, providing insights and innovative solutions for the ultra-sensitive detection of CPB. In this minireview, some of the advances, namely, chromogenic probes and methods, fluorogenic probes, dual fluorogenic–chromogenic probes, a chemiluminescent probe, and a novel label-free intracellular calorimetric approach, are summarized, appreciated, and discussed. These methods offer high sensitivity, specificity, and accuracy in a short period in clinical settings without the utilization of sophisticated equipment or professional personnel. We hope that this minireview can provide a reference for the development of rapid detection of CPB and eventually contribute to antibiotic resistance management.

Accurate and early diagnosis remains a key challenge in modern disease management. Conventional diagnostic methods often suffer from limitations in sensitivity, spatial resolution, and practical usability. Aggregation‐induced emission (AIE) luminogens (AIEgens) have emerged as a revolutionary material platform that effectively overcomes the aggregation‐caused quenching (ACQ) effect plaguing traditional fluorophores. Their unique AIE property endows them with exceptional attributes for diagnostic applications, including superior photostability, high signal‐to‐noise ratios and large Stokes shifts. In this review, we present a thorough and structured overview of recent progress in AIEgen‐based diagnostic strategies. The content is organized according to major disease categories: cancers, infectious diseases, neurological disorders, urinary system diseases and circulatory system diseases. For each category, we analyzed the design principles, sensing mechanisms, and analytical performance of AIE probes targeting diverse biomarkers such as proteins, nucleic acids, metabolites, and pathogens. We further discussed how AIEgens have been effectively integrated into point‐of‐care testing (POCT) platforms and portable devices, highlighting their potential for clinical translation. Finally, the promising future directions are outlined, such as the convergence of AIE technology with artificial intelligence for molecular design. This review aims to serve as a foundational reference and to inspire the rational design of next‐generation, AIEgen‐powered diagnostic technologies tailored to precision medicine.